Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five standard chemotherapy regimens in three common tumors - Part one: Model projections for cost based on charges

Cancer

Volumn 78, Issue 2, 1996, Pages 294-299

  Lokich, Jacob J ^a   Moore, Cherie L ^a   Anderson, Norwood R ^a  

^a Cancer Center of Boston   (United States)

Author keywords

breast cancer; chemotherapy charge profile; colon cancer; cost analysis; lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PREDNISONE; VINCRISTINE SULFATE;

ARTICLE; BOLUS INJECTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON CANCER; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DRUG DELIVERY SYSTEM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONIC NEOPLASMS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DISPOSABLE EQUIPMENT; DOXORUBICIN; DRUG COSTS; ETOPOSIDE; FEES, MEDICAL; FEES, PHARMACEUTICAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; METHOTREXATE; MODELS, ECONOMIC; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 0030056443     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<294::AID-CNCR16>3.0.CO;2-R     Document Type: Article

References (9)

1. Anderson N, Lokich J. Cancer chemotherapy and infusional scheduling. Oncology 1994;8(5):99-111.
2. Lokich JJ, Moore C, Anderson NR. Continuous Infusion Chemotherapy. Contemp Oncol 1993;3:35-47.
3. Lokich J, Anderson N. Infusional cancer chemotherapy: historical evolution and future development at The Cancer Center of Boston. Cancer Invest 1995;13(2):202-26.
4. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
5. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136-42.
6. Seifen P, Baker LH, Reed MD, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in patients with colorectal adenocarcinoma. Cancer 1975;36:123-8.
7. Lokich JJ, Ahlgren J, Gullo J, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusional 5fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
8. Engelsman E, Klijn JCM, Rubens J, Wildiers J, Beex LV, Nooij MA, et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 1991;27:966-70.
9. Lokich J, Anderson N. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration and cost comparisons. Cancer 1992;70:998-1002.